

ASX RELEASE

21 December 2021

**Change of Director's Interest Notice – Appendix 3Y: Dr Warwick Tong**

Appendix 3Y Change of Director's Interest Notice for Dr. Warwick Tong is attached.

This ASX announcement was approved and authorised for release by the Company Secretary of Amplia Therapeutics Limited.

- End -

**For further information:**

Andrew J. Cooke  
Company Secretary  
[andrew@ampliatx.com](mailto:andrew@ampliatx.com)  
[www.ampliatx.com](http://www.ampliatx.com)

**About Amplia Therapeutics Limited**

Amplia Therapeutics Limited is an Australian pharmaceutical company advancing a pipeline of Focal Adhesion Kinase (FAK) inhibitors for cancer and fibrosis. FAK is an increasingly important target in the field of cancer immunology and Amplia has a particular development focus in pancreatic and ovarian cancer. FAK also plays a significant role in a number of chronic diseases, such as idiopathic pulmonary fibrosis (IPF).

# Appendix 3Y

## Change of Director's Interest Notice

*Information or documents not available now must be given to ASX as soon as available. Information and documents given to ASX become ASX's property and may be made public.*

Introduced 30/09/01 Amended 01/01/11

<b>Name of entity</b>	<b>Amplia Therapeutics Limited</b>
<b>ABN</b>	16 165 160 841

We (the entity) give ASX the following information under listing rule 3.19A.2 and as agent for the director for the purposes of section 205G of the Corporations Act.

<b>Name of Director</b>	<b>Warwick Bonner Tong</b>
<b>Date of last notice</b>	18 September 2020

### Part 1 - Change of director's relevant interests in securities

*In the case of a trust, this includes interests in the trust made available by the responsible entity of the trust*

Note: In the case of a company, interests which come within paragraph (i) of the definition of "notifiable interest of a director" should be disclosed in this part.

<b>Direct or indirect interest</b>	Direct
<b>Nature of indirect interest (including registered holder)</b> <small>Note: Provide details of the circumstances giving rise to the relevant interest.</small>	
<b>Date of change</b>	15 December 2021
<b>No. of securities held prior to change</b>	2,355,140 Fully Paid Ordinary Shares 400,000 Fully Paid Ordinary Shares  40,000 Options Exercise Price A\$0.15 Expiry Date 30 June 2022 125,000 Options Exercise Price A\$0.15 Expiry Date 30 June 2022
<b>Class</b>	Fully Paid Ordinary Shares ATXO Listed Options Ex Price \$0.28 Exp 31 Dec 2023
<b>Number acquired</b>	100,000 Shares 33,334 ATXO Listed Options

---

+ See chapter 19 for defined terms.

## Appendix 3Y Change of Director's Interest Notice

<b>Number disposed</b>	Nil
<b>Value/Consideration</b> Note: If consideration is non-cash, provide details and estimated valuation	\$0.18 per share (with free attaching Option on 1 for 3 basis)
<b>No. of securities held after change</b>	2,355,140 Fully Paid Ordinary Shares 500,000 Fully Paid Ordinary Shares  40,000 Options Exercise Price A\$0.15 Expiry Date 30 June 2022 125,000 Options Exercise Price A\$0.15 Expiry Date 30 June 2022 33,334 ATXO Listed Options Ex Price \$0.28 Exp 31 Dec 2023
<b>Nature of change</b> Example: on-market trade, off-market trade, exercise of options, issue of securities under dividend reinvestment plan, participation in buy-back	Participation in Entitlement Offer

### Part 2 – Change of director's interests in contracts

Note: In the case of a company, interests which come within paragraph (ii) of the definition of "notifiable interest of a director" should be disclosed in this part.

<b>Detail of contract</b>	Nil
<b>Nature of interest</b>	
<b>Name of registered holder (if issued securities)</b>	
<b>Date of change</b>	
<b>No. and class of securities to which interest related prior to change</b> Note: Details are only required for a contract in relation to which the interest has changed	
<b>Interest acquired</b>	
<b>Interest disposed</b>	
<b>Value/Consideration</b> Note: If consideration is non-cash, provide details and an estimated valuation	
<b>Interest after change</b>	

+ See chapter 19 for defined terms.

**Part 3 – +Closed period**

<b>Were the interests in the securities or contracts detailed above traded during a +closed period where prior written clearance was required?</b>	No
<b>If so, was prior written clearance provided to allow the trade to proceed during this period?</b>	
<b>If prior written clearance was provided, on what date was this provided?</b>	

21 December 2021

---

+ See chapter 19 for defined terms.